Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Cosa Resources reports partner-funded airborne radiometric survey results at Aurora uranium project in Saskatchewan

Cosa Resources reports partner-funded airborne radiometric survey results at Aurora uranium project in Saskatchewan

ReutersReuters2026/08/04 12:08
  • Cosa reported results from a partner-funded airborne radiometric survey at its Aurora uranium project in Saskatchewan’s Athabasca Basin.
  • Survey identified multiple uranium-source radiometric anomalies near prospective basement features; high-resolution magnetic modelling refined the basement geology interpretation.
  • Work was fully funded by Traction Uranium under a Feb. 10, 2026 option to earn up to an 80% Aurora interest by sole-funding $9.15 million.
  • Data integration is ongoing; an inaugural drill program is scheduled for fall 2026, funded 100% by Traction.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cosa Resources Corp. published the original content used to generate this news brief via Newsfile (Ref. ID: 202608040800NEWSFILECNPR____20260804_307861_1) on August 04, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage

Eli Lilly stated on Monday that its oral weight-loss drug, Foundayo, has captured over 30% of the market share among new patients in the US oral obesity treatment market, narrowing the early lead achieved by Danish competitor Novo Nordisk with its Wegovy oral tablets.

智通财经2026/09/15 03:21
Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage